HC Wainwright Estimates Immunic's Q1 Earnings (NASDAQ:IMUX)

Key Points

• HC Wainwright raised its Q1 2026 EPS estimate for Immunic to ($0.20) from ($2.00) and maintains a Buy rating with a $22 price target.
• Analyst coverage is mixed but the consensus is a Moderate Buy with a consensus price target of $52.43 (two Strong Buy, six Buy, one Hold, one Sell).
• Immunic trades around $9.65 with a market cap of $131.4M and a 52‑week range of $5.06–$15.10, and it reported a recent quarterly EPS loss of ($1.20) versus consensus ($1.02).

Immunic, Inc. (NASDAQ:IMUX - Free Report) - Stock analysts at HC Wainwright raised their Q1 2026 earnings per share (EPS) estimates for Immunic in a report issued on Thursday, April 30th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($0.20) per share for the quarter, up from their prior forecast of ($2.00). HC Wainwright currently has a "Buy" rating and a $22.00 price objective on the stock. The consensus estimate for Immunic's current full-year earnings is ($3.44) per share. HC Wainwright also issued estimates for Immunic's Q2 2026 earnings at ($2.06) EPS, Q3 2026 earnings at ($1.89) EPS, Q4 2026 earnings at ($1.60) EPS, FY2026 earnings at ($2.61) EPS, FY2027 earnings at ($6.01) EPS, FY2028 earnings at ($3.66) EPS, FY2029 earnings at ($2.36) EPS and FY2030 earnings at ($1.08) EPS.

IMUX has been the topic of a number of other research reports. Wall Street Zen lowered Immunic from a "hold" rating to a "sell" rating in a research report on Sunday, April 19th. Guggenheim began coverage on Immunic in a research report on Tuesday, March 24th. They set a "buy" rating and a $70.00 price target on the stock. D. Boral Capital lowered Immunic from a "buy" rating to a "hold" rating in a research report on Wednesday, April 15th. Stifel Nicolaus set a $25.00 price target on Immunic and gave the stock a "buy" rating in a research report on Thursday, April 16th. Finally, raised shares of Immunic to a "strong-buy" rating in a research report on Tuesday, February 3rd. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $52.43.

Immunic Stock Performance

Immunic stock opened at $9.65 on Monday. The firm has a market capitalization of $131.43 million, a PE ratio of -1.38 and a beta of 1.20. The business's 50-day simple moving average is $11.07 and its 200-day simple moving average is $8.40. Immunic has a 52 week low of $5.06 and a 52 week high of $15.10.

Immunic (NASDAQ:IMUX - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($1.20) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.18).

Hedge Funds Weigh In On Immunic

Hedge funds have recently made changes to their positions in the business. Qube Research & Technologies Ltd acquired a new stake in shares of Immunic in the third quarter valued at approximately $29,000. Focus Partners Wealth grew its position in Immunic by 1.5% in the third quarter. Focus Partners Wealth now owns 2,581,587 shares of the company's stock valued at $2,276,000 after purchasing an additional 39,063 shares in the last quarter. Two Sigma Investments LP bought a new position in Immunic in the third quarter valued at $52,000. Squarepoint Ops LLC increased its stake in Immunic by 29.9% in the 4th quarter. Squarepoint Ops LLC now owns 352,875 shares of the company's stock valued at $188,000 after buying an additional 81,301 shares during the last quarter. Finally, Jane Street Group LLC lifted its position in Immunic by 46.8% during the 4th quarter. Jane Street Group LLC now owns 286,677 shares of the company's stock worth $153,000 after buying an additional 91,346 shares in the last quarter. 51.82% of the stock is owned by institutional investors.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company's research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic's lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn's disease and relapsing multiple sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.